Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375114 · ClinicalTrials.gov registry record · Phase 1
The Effects of Ginseng on Cancer-Related Fatigue
A Phase 1 study of Solid Tumors and Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 1
- Study location
NCT01375114 is a Phase 1 study of Solid Tumors and Advanced Cancers that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 165 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01375114, a Phase 1 study of Solid Tumors and Advanced Cancers, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if panax ginseng (commonly called ginseng) can help to control fatigue and other symptoms such as depression, anxiety, and mood changes in patients with cancer. The safety of ginseng will also be studied.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- BEHAVIORAL Questionnaires
- DRUG Panax Ginseng
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2011-10-14 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01375114
The ClinicalTrials.gov registry entry for NCT01375114 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (42% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01375114 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01375114 about?
NCT01375114 is a clinical study titled "The Effects of Ginseng on Cancer-Related Fatigue". The goal of this clinical research study is to learn if panax ginseng (commonly called ginseng) can help to control fatigue and other symptoms such as depression, anxiety, and mood changes in patients with cancer. The safety of ginseng will also be studied.
What is the current status of trial NCT01375114?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2011-10-14. Estimated completion is 2025-10-31.
What conditions does trial NCT01375114 study?
This clinical trial studies the following conditions: Solid Tumors, Advanced Cancers.
What interventions are being tested in trial NCT01375114?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Questionnaires (BEHAVIORAL), Panax Ginseng (DRUG).
Who is sponsoring clinical trial NCT01375114?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01375114 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.